Gilpure M2 Forte Tablet IR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves insulin sensitivity in peripheral tissues, enhancing glucose uptake and utilization. The immediate-release formulation ensures rapid onset of action, facilitating effective glycemic control. Gilpure M2 Forte is prescribed as part of a comprehensive diabetes management plan including diet, exercise, and weight control. It is particularly beneficial for patients inadequately controlled on monotherapy or requiring combination therapy to achieve target glycemic levels. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and hypoglycemia, especially when combined with other antidiabetic agents. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia. Regular monitoring of blood glucose, renal function, and lactic acid levels is recommended during therapy. Gilpure M2 Forte should be used under medical supervision to optimize therapeutic outcomes and minimize potential risks associated with combination therapy in type 2 diabetes mellitus.